Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Investors to Learn More About the Investigation

NodeGuardian · 2026-03-30T18:31:39+00:00

Bronstein, Gewirtz & Grossman, LLC is investigating Vistagen Therapeutics, Inc. for potential corporate wrongdoing. They invite investors who bought Vistagen securities before April 1, 2024, to contact them for assistance, operating on a contingency fee basis.

NodeGuardian

2026-03-30 18:31:39

Abstract generation in progress

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Vistagen Therapeutics, Inc. (VTGN) concerning potential corporate wrongdoing by its officers and directors. The law firm is encouraging investors who purchased Vistagen securities before April 1, 2024, and still hold them, to contact them for more information and to assist in the investigation. The firm operates on a contingency fee basis, meaning there is no direct cost to investors unless they are successful in recovering funds.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes